Somewhat Favorable News Coverage Somewhat Unlikely to Impact Spark Therapeutics (ONCE) Stock Price
News coverage about Spark Therapeutics (NASDAQ:ONCE) has been trending somewhat positive on Thursday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 48.0600037408412 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Spark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE) (americanbankingnews.com)
- Oversold Conditions For Spark Therapeutics (ONCE) – Nasdaq (nasdaq.com)
- Barge Joseph La Sells 3,309 Shares of Spark Therapeutics, Inc. (ONCE) Stock (americanbankingnews.com)
- Barge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) Stock (americanbankingnews.com)
Several analysts have recently weighed in on ONCE shares. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday, October 6th. Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. BMO Capital Markets set a $89.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 10th. Raymond James Financial, Inc. started coverage on shares of Spark Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $96.00 price objective for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a research report on Friday, October 13th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $90.36.
Shares of Spark Therapeutics (NASDAQ ONCE) traded up $3.72 during trading on Thursday, reaching $73.08. The company had a trading volume of 495,412 shares, compared to its average volume of 398,888. Spark Therapeutics has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the prior year, the firm posted ($1.07) earnings per share. The company’s revenue was up 45.8% on a year-over-year basis. equities analysts anticipate that Spark Therapeutics will post -7.67 earnings per share for the current fiscal year.
In other news, insider Barge Joseph La sold 5,500 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $81.00, for a total transaction of $445,500.00. Following the completion of the transaction, the insider now owns 10,825 shares of the company’s stock, valued at $876,825. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now directly owns 1,500 shares of the company’s stock, valued at approximately $127,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,099,659 shares of company stock worth $92,457,658. Company insiders own 7.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-spark-therapeutics-once-stock-price.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.